Altered Ras superfamily guanine nucleotide triphosphatase signaling may contribute to the activation of autoreactive T cells in diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here, we show that transgenic expression of activated Rap1, a Ras-related protein which is protective in murine arthritis, in both wildtype (WT) and 2D2 mice, enhances autoreactive T cell activation by myelin oligodendrocyte glycoprotein peptide in vitro and in vivo. However, RapV12 reduces the number of autoreactive T cells in both WT and 2D2 mice, and increases murine survival in experimental autoimmune encephalitis, suggesting Rap1 activation restricts autoimmune T cell-mediated pathology through enhancing tolerance.
Introduction
T cells specific for self-antigens have been proposed to play a pivotal role in many autoimmune diseases. This pathogenic concept relies on several lines of evidence. Firstly, genetic analysis revealed an association of several autoimmune diseases with MHC class II molecules, such as HLA-DR4 in rheumatoid arthritis (RA), as well as with other molecules involved in T cell activation or T cell receptor (TCR) signaling. As a prototypical example, genetic polymorphisms in PTPN22, a critical inhibitor in T cell receptor signaling, are associated with susceptibility to RA, type 1 diabetes (T1D), and systemic lupus erythematosus (SLE) (Gregersen, 2005) . Secondly, clonally expanded CD4+ T cell populations are present in the primary target tissues or draining lymph nodes (LN) in autoimmune diseases such as RA and T1D (Kent et al., 2005; Cantaert et al., 2009) . Thirdly, functional analyses have demonstrated critical contributions of autoreactive T cells to pathology in several animal disease models. In the NOD mouse, CD4+ T cells are essential both in the early and late stages of T1D and directly contribute to the destruction of pancreatic β-cells (Anderson and Bluestone, 2005) . In experimental autoimmune encephalomyelitis (EAE), severe central nervous system damage is caused by the activation of myelin-specific T cells as evidenced by TCR transgenic models and transfer experiments with pathogenic T cells (Kuchroo et al., 2002) . In collagen-induced arthritis (CIA), effector CD4 T cells produce pro-inflammatory cytokines and stimulate B cells to produce anti-collagen type II antibodies critical to the promotion of pathology (Brand et al., 2003) . Fourthly, the use of T cell targeted therapies has proven efficacy in several human autoimmune diseases, including the targeting of effector T cells with alefacept in psoriasis (Ellis and Krueger, 2001) , costimulation blockade with CTLA4-Ig in RA (Kremer et al., 2003) , and anti-CD3 therapy in T1D (Keymeulen et al., 2005) .
Recent research has focused on the identification of specific intracellular signaling pathways that control the development, expansion, and activation of autoreactive T cells as these pathways may form attractive candidates for therapeutic modulation in autoimmune disease. Members of the Ras superfamily of small guanine nucleotide triphosphatases (GTPases), particularly Ras and Rap1 GTPases, have emerged as key candidates. Activation of both Ras and Rap1 GTPases in T lymphocytes is mediated by their binding to GTP following TCR ligation or chemokine stimulation (Genot and Cantrell, 2000; Minato et al., 2007) and alterations in these signaling pathways have been linked to autoimmune disease. For example, partial inactivation of T cell Ras, as observed in mice deficient for RasGRP1, a guanine nucleotide exchange factor (GEF) which couples TCR ligation to Ras activation, results in spontaneous SLE-like pathology (Layer et al., 2003) . This is not due to overall T cell hyperreactivity, as peripheral T cell numbers and proliferative responses are reduced in these mice, but rather to inefficient negative selection of autoreactive T cells by self-antigen in the thymus (Layer et al., 2003; Priatel et al., 2006 Priatel et al., , 2007 . Strikingly, Ras-dependent T cell signaling and proliferative responses are suppressed in SLE patient peripheral blood T cells, associated with decreased expression and function of Ras GEFs (Cedeno et al., 2003; Yasuda et al., 2007) .
A potential role for Rap1 in human T cell-mediated autoimmune disease was first suggested by the fact that Rap1 is inactivated in RA synovial fluid T cells and that this is associated with the persistent production of reactive oxygen species (ROS) and hyper-responsive cytokine production following TCR triggering (Remans et al., 2004 (Remans et al., , 2006 Abreu et al., 2009) . Similarly to Ras, Rap1 is activated by TCR and adhesion molecule ligation, as well as by chemokine stimulation (Minato et al., 2007) . Once activated, Rap1 orchestrates the assembly of adaptor proteins and activation of downstream kinases needed for integrin-mediated trafficking of T cells to lymphoid organs and their adhesion to antigen presenting cells (APCs). In mice, genetic inactivation of T cell Rap1 leads to an agedependent accumulation of activated T cells in peripheral lymphoid organs (Dillon et al., 2005) . Conversely, constitutive activation of T cell Rap1 results in age-dependent hyporesponsiveness to antigenic challenge (Ishida et al., 2003; Li et al., 2005) . Constitutive activation of Rap1 can also antagonize Ras-dependent mitogen-activated protein kinase (MAPK) activation, likely via indirect effects of Rap1 on T cell ROS production (Boussiotis et al., 1997; Bos et al., 2001; Remans et al., 2004) .
To directly assess the impact of T cell Rap 1 signaling on autoimmunity, we recently examined mice expressing a hypermorphic mutant of Rap1A (RapV12) in the T cell compartment and found that these mice were protected from CIA (Sebzda et al., 2002; Abreu et al., 2010) . Protection against pathology in this model was associated with specific in vivo defects in TNFα production by CD8+ LN T cells during arthritis onset, and a failure of RapV12 mice to generate high titers of anti-collagen antibodies. However, further mechanistic insight as to how sustained T cell Rap1 activation protected mice against autoimmunity in CIA was hampered by the inability to track the activation and fate of autoantigen-specific T cells in this model. In the present study, we examined the role of T cell Rap1 activation in myelin oligodendrocyte glycoprotein (MOG)-induced EAE, an autoimmune disease mediated by pathogenic autoreactive T cells without major contribution of autoantibodies. In this model, specific auto-reactive T cells can be studied using a transgenic 2D2 mouse in which all T lymphocytes bear TCRs specific for the immunodominant epitope MOG and can be tracked by their TCR β-chain Vβ11 (Bettelli et al., 2003) . Auto-reactive T cells can also be studied with tetramer staining of MOG-specific TCRs (Sabatino et al., 2011) . Taking advantage of these features, we first studied the effect of sustained Rap1 activation on the quality of the autoreactive T cell response in terms of proliferation, activation and cytokine production. Subsequently, we analyzed the quantitative effects on the size of the autoreactive T cell pool. Finally, we assessed whether the qualitative and quantitative effects translated in attenuation of clinical disease.
Materials and methods

Animals
Transgenic C57BL/6 J mice expressing hypermorphic RapV12 under the control of the CD2 promoter were provided by Dr. D.A. Cantrell (University of Dundee, Dundee, UK) (Sebzda et al., 2002) . 2D2 transgenic C57BL/6 J mice were provided by Dr. V. Kuchroo (Harvard Medical School, Boston, MA, USA) (Bettelli et al., 2003) . RapV12 transgenic animals were crossed with 2D2 mice and the F1 generation of 2D2+ RapV12-and 2D2+ RapV12+ were used for EAE experiments. All animals were housed under conventional conditions in the animal facility of the Academic Medical Center/University of Amsterdam (Amsterdam, The Netherlands). All experiments were performed according to local regulations and were approved by the Animal Ethics Committee of the Academic Medical Center/University of Amsterdam.
Induction and assessment of EAE
Mice (8-12 weeks of age) were immunized subcutaneously in two sites of the neck on day 0 with 100 μg of MOG peptide (amino acid residues 35-55, sequence MEVGWYRSPFSRVVHLYRNGK) (AnaSpec, Freemont CA, USA) emulsified in complete Freund's adjuvant (CFA) (Chondrex, Bellevue WA, USA) supplemented with 400 μg/ml of M. tuberculosis (Difco Laboratories, Sparks MD, USA). Additionally, mice were injected intravenously on days 0 and 2 with 150 ng of pertussis toxin (Sigma-Aldrich, St. Louis MI, USA). Following immunization, the animals were scored 3 times per week until onset of EAE. After onset of clinical EAE, scoring was performed daily until day 30 after immunization. A 5-point scale was used to evaluate signs of neurological disease: 0, no disease; 1, decreased tail tone; 2, hindlimb weakness or partial paralysis; 3, complete hind-limb paralysis; 4, front and hind limb paralysis. Mice that reached a score of 4 were euthanized immediately for ethical reasons.
Flow cytometric detection of surface proteins
Spleen and LN were collected from non-immunized mice and from animals 10 days after immunization with MOG. Single-cell suspensions were obtained, erythrocytes removed, and cells were then stained at 4°C with the indicated fluorochrome-conjugated anti-mouse monoclonal antibodies for surface markers or with isotype-and concentrationmatched control antibodies. Antibodies used in this study included Alexa700-conjugated anti-CD3, Alexa700-conjugated anti-CD4, phycoerythrin (PE)-Cy7-conjugated anti-CD4, Alexa 780-conjugated anti-CD8, PE-conjugated anti-vβ11, FITC-conjugated anti-CD44 and PerCP-Cy5.5-conjugated anti-CD62L (eBioscience CA, San Diego, USA). For tetramer staining of MOG-reactive T cells, CD4 T cells were purified using an anti-CD4 antibody and LS columns (Miltenyi Biotech GmbH., Bergisch Gladbach, Germany) according to manufacturer's instructions. CD4+ T cells were incubated overnight with 4 μg/ml of MOG 38-49 IA b or negative control hCLIP 103-117 IA b tetramers (Sabatino et al., 2008 (Sabatino et al., , 2011 . Flow cytometric analysis was performed and analyzed using a 7-color FACS Canto (BD Biosciences, San Jose CA, USA) and FlowJo software (Tree Star Inc., Ashland OR, USA). The results were expressed as % of positive cells.
T cell stimulation and detection of costimulatory molecules, cytokine production and proliferation
To detect the expression of costimulatory molecules and the production of intracellular cytokines, 4 × 10 6 cells/ml in RPMI supplemented with 10% FCS, β-mercaptoethanol, L-glutamine, gentamicin sulfate and penicillin/streptomycin, were stimulated in 96-well plates for 6 h with phorbol myristate acetate (PMA, 10 ng/ml; Sigma-Aldrich) and ionomycin (1 μM; Sigma-Aldrich). Alternatively cells were cultured with medium alone or medium supplemented with MOG peptide (3 or 10 μg/ml) or anti-CD3 (5 μg/ml) and anti-CD28 antibodies (5 μg/ml) (both provided by Dr. L. Boon, Bioceros BV, Utrecht, NL) for 24 or 48 h. For the detection of intracellular cytokines, Brefeldin A (5 μg/ml; Sigma-Aldrich) was added for the last 4 h of culture, and cells were fixed and permeabilized using a BD intracellular staining kit (BD BioSciences). Cells were stained with FITC-conjugated PD-1, PE-conjugated ICOS, APC-conjugated CD40L, Alexa 488-conjugated anti-IL-17, PerCP-Cy5.5-conjugated anti-IFN-γ, PE-Cy7-conjugated anti-IL-2, and APC-conjugated anti-TNFα (eBiosciences, San Diego, USA). To assess proliferative capacity, cells were labeled with carboxyfluorescein succinimidyl ester (CFSE, 1 μg/ml; Molecular Probes, Eugene OR, USA) and subsequently stimulated for 72 h in the absence or presence of MOG peptide or anti-CD3/CD28 antibodies. Cells were then analyzed for CFSE dilution, mean number of cell divisions and precursor frequency by flow cytometry. Staining with 7-aminoactinomycin D (BD Biosciences) was used to exclude dead cells. The results were expressed as percentage of positive cells or as mean fluorescence intensity (MFI) after subtracting the signal of a matched isotype control.
Statistics
Numerical data were depicted in a box plot and the variation was described by median and interquartile range (IQR). Gehan-BreslowWilcoxon test was used to compare the incidence of EAE and the survival proportions between groups of mice. The severity of EAE per group was assessed by calculating the area under the curve for each mouse in the group, and groups were compared using a MannWhitney non-parametrical t-test. Flow cytometric data were compared using Mann-Whitney non-parametrical t-test. P-values ≤ 0.05 were considered statistically significant.
Results
Sustained Rap1 activation promotes autoreactive T cell hyperresponsiveness
Previous reports indicated that Rap1-GTP levels are elevated in anergic T cells and that T cell Rap1 activation can dampen antigenspecific proliferation (Boussiotis et al., 1997; Sebzda et al., 2002) . In order to determine whether similar effects are observed in MOGspecific T lymphocytes, we recovered autoreactive T cells (Bettelli et al., 2003) from the spleens of 2D2 + RapV12+ and 2D2+ RapV12-animals, stimulated these cells in vitro, and determined their capacity to proliferate, produce IL-2, and upregulate the expression of costimulatory molecules. Autoreactive Vβ11+ CD4+ T cells recovered from naïve 2D2 +RapV12+ mice proliferated more than their counterparts from 2D2+ RapV12-animals, both upon non-specific stimulation with anti-CD3/CD28 (p =0.017) and upon MOG peptide stimulation (p = 0.004 and p =0.030 for 1 μg/ml and 3 μg/ml MOG, respectively) ( Fig. 1A) . Confirming that the RapV12 mutant did not induce anergy of autoreactive T cells, IL-2 production was maintained upon anti-CD3/ CD28 stimulation and even increased upon MOG stimulation (p = 0.044 with 3 μg/ml) (Fig. 1B) . Also ICOS expression was increased upon MOG stimulation (p= 0.004 with 3 μg/ml and p= 0.030 with 10 μg/ml MOG) (Fig. 1C) in the 2D2+ RapV12+ animals. This was specific for the autoreactive cells as we noted only a slight but significant increase in MOG-specific proliferation of Vβ11-CD4+ T cells in double transgenic animals (Fig. 1D) , and no differences in IL-2 production (Fig. 1E ) or ICOS expression (Fig. 1F ) between single and double transgenic animals. Expression levels of other costimulatory molecules such as PD-1 and CD40L were comparable between 2D2 +RapV12-and 2D2+ RapV12+ lymphocytes (data not shown). Similar experiments with T cells recovered from animals 10 days after immunization with MOG to mimic recall rather than primary responses, further confirmed these findings. Also in this experimental setting, the autoreactive T cells displayed significantly increased IL-2 production (p= 0.008 with anti-CD3/CD28 stimulation and p =0.036 with 3 μg/ml and 10 μg/ml MOG) ( Fig. 2A) and ICOS expression (p =0.015 with 3 μg/ml and p= 0.031 with 10 μg/ml MOG) (Fig. 2B ) in the presence of the hypermorphic RapV12 mutant, while no differences in the responsiveness of Vβ11-CD4+ T cells were observed ( Fig. 2C-D) . Taken together, these data indicate that the autoreactive T cells are not anergic but rather hyperresponsive in the RapV12 animals.
Sustained activation of Rap1 does not impair cytokine production by autoreactive T cells
As CD4+ T lymphocytes producing IFNγ and IL-17 are the main effector cells contributing to central nervous system inflammation in MOG-induced EAE (Jager et al., 2009; El-behi et al., 2010) , we next assessed whether the increased proliferation and ICOS expression of the autoreactive T cells in the presence of RapV12 functionally translated in altered production of pro-inflammatory cytokines. In vitro MOG restimulation of Vβ11 + CD4+ T lymphocytes recovered Fig. 1 . Autoreactive T cells are hyperresponsive, not anergic in RapV12 mice. Splenocytes from naive 2D2 + RapV12-and 2D2 + RapV12 + mice (A, D) were stained with CFSE and cultured with medium, anti-CD3/CD28 antibodies and MOG peptide. After 3 days, the percentages of proliferating Vβ11 + CD4 + (A) and Vβ11-CD4 + (D) T lymphocytes were calculated by CFSE dilution. Splenocytes from 2D2 + RapV12-and 2D2 + RapV12 + naïve mice were stimulated with medium, anti-CD3/anti-CD28 antibodies and MOG peptide for 24-48 h. The percentages of Vβ11 + CD4 + (B, C) and Vβ11-CD4 + (E, F) T lymphocytes producing IL-2 (B, E) or expressing ICOS (C, F) were analyzed by flow cytometry. Mann-Whitney test was used to compare groups (*p-value ≤ 0.05).
10 days after in vivo immunization revealed no difference in IL-17 and IFNγ expression between 2D2+RapV12-and 2D2+RapV12+ mice ( Fig. 3A and B, respectively). Increased TNFα expression was observed upon anti-CD3/CD28 stimulation (p=0.056) and low dose MOG stimulation (p =0.032 for 3 μg/ml) in the autoreactive T cells recovered from the 2D2+RapV12+ compared to 2D2+RapV12-mice (Fig. 3C) . A similar analysis of vβ11 +CD4+ T cells from naïve mice did not show any differences between 2D2 +RapV12-and 2D2+RapV12+ animals for these three cytokines (Fig. 3D-F) . Confirming the specificity of these findings, an analysis of the vβ11-CD4+ T cells, which do not bear the MOGspecific TCR transgene, did not show any cytokine production at all upon MOG stimulation in either naïve or immunized 2D2 +RapV12-and 2D2+RapV12+ animals (data not shown). Furthermore, we repeated this experiment using PMA/ionomycin for in vitro restimulation of vβ11+CD4+ autoreactive T cells that were primed in vivo by MOG immunization. In this experimental setting, we observed a trend towards an increase in the production of IL-17 and similar expression of IFNγ and TNFα in 2D2+RapV12-and 2D2+RapV12+ animals (data not shown). These data indicate that constitutive Rap1 signaling does not markedly modulate the production of pathogenic cytokines by MOGspecific autoreactive T cells in this model.
Sustained activation of Rap1 does not induce activation-induced cell death of autoreactive T cells
Based on the reported effects of Ras guanyl-releasing protein 1 (GRP1) defects on thymic selection and autoimmunity (Amsen et al., 2000; Priatel et al., 2002) , we next considered the possibility that Rap1 activation may affect the size of the autoreactive T cell pool by either peripheral or central deletion of MOG-reactive T cells. We first assessed whether the increased ex vivo proliferation upon MOG stimulation was associated with changes in activation-induced cell death (AICD) of autoreactive T cells in the presence of sustained Rap1 signaling (Green et al., 2003) . As in the previously described proliferation assays, we recovered splenic T cells from 2D2 + RapV12+ and 2D2 +RapV12-mice and stimulated them in vitro with MOG peptide for 3 days. The survival of autoreactive T cells as measured by the percentage of 7-AADnegative vβ11 + CD4+ T cells was significantly increased in the 2D2+ RapV12+ samples versus the 2D2 + RapV12-controls after stimulation with MOG peptide (p = 0.038 with 1 μg/ml and p= 0.018 after stimulation with 3 μg/ml MOG, Fig. 4A ). The vβ11-CD4+ population, which does not express the autoreactive TCR, did not display these changes in survival (data not shown). Repeating these experiments with T cells recovered 10 days after in vivo priming with MOG yielded an increased percentage of living T cells in 2D2 + RapV12+ lymphocytes when compared to 2D2+ RapV12-after stimulation with anti-CD3/ CD28 antibodies (p= 0.015, Fig. 4B ). In line with the in vitro data, ex vivo phenotypic analysis of the splenic T cells 10 days after immunization with MOG revealed a significantly increased accumulation of effector (p= 0.008) and central memory (p = 0.055) autoreactive T cells and a reciprocal decrease of naïve Vβ11+ CD4+ T cells (p= 0.008) in the 2D2+ RapV12+ versus the 2D2 + RapV12-animals ( Fig. 4C-E) . This difference was specifically related to the response to MOG priming as the percentages of naïve, effector, and central memory cells were similar between the two strains under homeostatic conditions (data not shown). These in vitro and in vivo data indicate that increased MOGinduced proliferation of autoreactive T cells in the presence of sustained Rap1 is not a consequence of changes in AICD.
Sustained activation of Rap1 affects the size of the autoreactive T cell pool
We next assessed whether the hypermorphic RapV12 mutant may have quantitative effects on the size of the pool of autoreactive T cells in 2D2+ RapV12+ animals. Analysis of MOG-immunized animals showed that the frequency of Vβ11 + CD4+ T cells in the total splenocyte population was significantly diminished in the 2D2+ RapV12+ versus 2D2 + RapV12-animals (medians 11 versus 15%, p = 0.007, Fig. 5A ). As the autoreactive T cells form 85% of the total T cell repertoire in the 2D2 mice, the number of CD3 + CD4+ T cells was equally reduced in the double transgenic animals relative to the single transgenic controls (medians 14 versus 23%, p = 0.03, Fig. 5B ). Accordingly, trends towards reduced numbers of Vβ11 + CD4+ and CD3 + CD4+, but not CD8+ or FoxP3+ T cells were observed in spleens of immunized 2D2 + RapV12+ mice (Supplemental Fig. 1 ). Because our in vitro experiments did not provide evidence for AICD, we aimed to determine if this effect was due to homeostatic central or activation-dependent mechanisms by repeating the same experiment in naïve animals, prior to peripheral exposure to the autoantigen. Both the percentages of autoreactive Vβ11 + CD4+ T cells (medians 15 versus 27% p = 0.05) and of total CD4+ T cell (medians 17 versus 30%, p = 0.03) were decreased in the spleens of the naïve 2D2+ RapV12+ versus 2D2 + RapV12-animals ( Fig. 5C-D) , as were the total numbers of these cell populations (Supplemental Fig. 2 ). To assure that this was a reproducible effect of Rap1 signaling rather than an artifact due to the use of a specific TCR-transgenic model, we additionally quantified the frequency of MOG-specific T cells in wildtype (WT) animals 10 days after immunization with MOG peptide using peptide-MHC tetramers (Sabatino et al., 2008 (Sabatino et al., , 2011 The percentages of positive cells were compared using Mann-Whitney test (*p-value ≤ 0.05).
in RapV12 mice versus WT littermate controls (p= 0.04, Fig. 5E ). The percentages of MOG-autoreactive T cells were also decreased in the CD44+ effector and central memory T cells (p= 0.04, Fig. 5F ). Taken together, these experiments indicate that sustained Rap1 signaling reduces the size of the pool of autoreactive T cells.
Sustained Rap1 activation decreases mortality during experimental autoimmune encephalomyelitis
As we previously observed that RapV12 mice were protected from CIA (Abreu et al., 2010) , we next assessed whether the qualitative and quantitative effects of sustained Rap1 signaling on the MOG-autoreactive T cells translated in an altered disease incidence or severity in EAE. We first evaluated clinical disease in the 2D2 animals, where the strong bias of the T cell repertoire towards autoreactivity leads to rapid onset and very severe EAE upon MOG immunization (Bettelli et al., 2003) . Comparison of the 2D2+ RapV12+ double transgenic mice and 2D2+ RapV12-single transgenic littermate controls showed a slightly but not significantly decreased severity and incidence of EAE in the presence of RapV12, resulting in a significantly increased survival of these animals (p= 0.04, Fig. 6A-C) . As clinical effects may be blurred in this TCR transgenic model due to the high severity of disease, we repeated these experiments in RapV12 mice versus WT littermate controls. In these experiments, the overall disease scores in the WT mice were lower, with an incidence of almost 60% and a mean disease score of 2.3 in the affected mice, resulting in an overall disease score of approximately 1.3 (Fig. 6D) . Again we observed a clear trend towards decreased disease severity (p =0.070) (Fig. 6D ) and incidence (p =0.085) (Fig. 6E) in the RapV12 mice. Accordingly, the mortality rate was significantly lower in the RapV12 mice than in WT littermates (p=0.02, Fig. 6F ). In conclusion, these data indicate that sustained Rap1 signaling in T cells decreased mortality during MOG-induced EAE.
Discussion
Rap1 is an intracellular small GTPase, which is activated in T cells following TCR ligation, chemokine stimulation, and engagement of adhesion proteins. To date, regulation of the quality of T cell immune responses by Rap1 has been attributed to the proposed capacity of active Rap1 to suppress Ras-dependent MAP kinase proliferative pathways (Boussiotis et al., 1997) . In mice lacking Spa-1, a GAP for Rap1, an age-dependent decrease in T cell proliferation and cytokine production in response to anti-CD3/CD28 antibodies and recall antigen stimulation is observed (Ishida et al., 2003) . Similar defective T cell responses are reported in transgenic mice expressing constitutively active Rap1E63 in the T cell compartment (Li et al., 2005) . Conversely, decreasing Rap1 function by transgenic overexpression of RapGAP I in the T cell compartment leads to an age-dependent accumulation of T cells in lymphoid organs which display surface markers indicative of immune activation (Dillon et al., 2005) . Additionally, there is substantial evidence that activation of Rap1 regulates T cell functional responses by coordinating the activation of integrins required for T cell chemotactic responses and trafficking and for stable conjugation with APCs Menasche et al., 2007) . In vivo and in vitro experiments have demonstrated that activation-dependent association of Rap1 with the adaptor proteins RapL (regulator of adhesion and cell polarization enriched in lymphoid tissues), SKAP1 (src kinase-associated phosphoprotein 1) and ADAP (adhesion and degranulation-promoting adaptor protein), is required for clustering of T cell integrins, T cell homing to secondary LN, and productive arrest of T cells with APCs (Katagiri et al., 2003 (Katagiri et al., , 2004 (Katagiri et al., , 2006 Ebisuno et al., 2010; Raab et al., 2010) . Accordingly, transgenic expression of constitutively active RapE63 or hypermorphic RapV12 stimulates T cell integrin-dependent adhesion, while Rap1A −/− T cells display partial defects in TCR and chemokine-induced adhesion (Sebzda et al., 2002; Li et al., 2005) .
We have previously demonstrated that sustained T cell Rap1 activation is protective in experimental T cell-mediated autoimmune disease, but it remains largely unknown how the different effects of Rap1 on T cell interactions with APCs, proliferation and homing impact upon autoreactive T cells and modulate autoimmune disease in vivo (Abreu et al., 2010) . Using 2D2 TCR and RapV12 double transgenic mice, we were able to analyze the qualitative and quantitative impact of Rap1 signaling on MOG-autoreactive T cells and to assess how this translates into modulation of EAE. We considered possible effects of sustained T cell Rap1 activation on auto-reactive T cell proliferative responses, cytokine production, and survival, and found that each of these parameters was enhanced in mice expressing RapV12. However, this was offset by a decrease in the total numbers of autoreactive T cells, both on the 2D2 TCR transgenic background and in mice expressing endogenous TCR repertoires. This reduction in autoreactive T cell numbers appears clinically important, as despite the ability of RapV12 to enhance intrinsic T cell responses to MOG, 2D2+ RapV12+ and RapV12+ mice displayed enhanced survival during EAE.
In our analyses, we first considered the possibility that RapV12 may dampen antigen-specific T cell proliferative responses or induce anergy. Rap1-GTP levels are elevated in anergic T cells, and transgenic overexpression of constitutively active Rap1E63 reduces CD4+ T cell IL-2 production and proliferation induced by anti-CD3/CD28 stimulation and during antigen recall (Boussiotis et al., 1997; Li et al., 2005) . However, this is not observed in RapV12 mice and, in contrast, antigen-specific proliferation at low antigen concentrations is enhanced (Sebzda et al., 2002) . This difference between Rap1E63 and RapV12 mice is attributed to the ability of RapV12 to still cycle between the active and inactive state, albeit at a reduced level, and the relative overexpression of Rap1E63 compared to RapV12. In our analyses of RapV12 mice during CIA, we also failed to observe defective polyclonal proliferative responses to anti-CD3/CD28 stimulation (Abreu et al., 2010) . Here, we confirmed and extended these findings by demonstrating that RapV12 conferred a proliferative advantage not only upon polyclonal anti-CD3/CD28 stimulation but also upon MOG stimulation of the autoreactive T cells. This proliferative advantage was observed both during primary and recall responses to MOG and was associated with increased IL-2 production and upregulation of ICOS. Cumulatively, these data indicate that sustained Rap1 activation does not induce anergy but rather intrinsic hyperreponsiveness of the autoreactive T cells in this model.
A second possible effect of sustained Rap1 signaling which we studied was the modulation of cytokine production by autoreactive T cells. We previously observed that RapV12 mice displayed a selective impairment in TNFα production by CD8+ LN T cells during the early phases of CIA, possibly due to clonal exhaustion of specific T cell subsets (Abreu et al., 2010) . Here, specific analysis of the autoreactive CD4+ cells did not show any decrease for IFNγ and IL-17, which are the major pathogenic cytokines in EAE. For TNFα, the role of which remains more controversial in EAE (Ruddle et al., 1990; Klinkert et al., 1997; Liu et al., 1998; Dal Canto et al., 1999) , production was increased rather than decreased in the autoreactive T cell pool. Also, expression levels of PD-1, a marker of clonal exhaustion, were equivalent between 2D2 + RapV12+ and 2D2 + RapV12-MOG-specific T cells, and re-challenge of these autoreactive T cells with MOG peptide in vitro revealed no proliferative impairment which usually precedes loss of TNFα expression in viral models of clonal exhaustion (Wherry, 2011) . These data indicate that clonal exhaustion of MOG autoreactive CD4+ T cells does not occur in EAE, as the T cells maintain their ability to produce pathogenic cytokines. The apparent paradox between CIA and EAE models emphasizes that the biological effects of sustained Rap1 activation are certainly not restricted to the autoreactive T cell pool, as assessed in the present study of EAE. This concept is very important as not only the pathogenic autoreactive T cells but also other T cell populations such as CD8+ T cells and regulatory T cells will ultimately contribute to determine the clinical disease severity and phenotype.
Besides the impact on the quality of the autoreactive T cell responses, we also considered the possibility that Rap1 activation could affect the size of the autoreactive T cell pool. A first reason to propose a quantitative effect is that the proliferative advantage of T cell lines expressing active Rap1 is offset by enhanced AICD (Katagiri et al., 2002) . However, we could obtain no evidence that this happens during autoimmune disease in the 2D2 + RapV12+ mice as 2D2 + RapV12+ T cells instead showed a survival advantage compared to 2D2 +RapV12-T cells following ex vivo stimulation with anti-CD3/CD28 antibodies or MOG peptide. Additionally, we observed an enhanced accumulation of effector and memory autoreactive T cells upon MOG immunization in the 2D2 + RapV12+ animals. These results are similar to the recently reported observations that the Rap1 effector ADAP augments T cell proliferation and survival in response to limiting antigen concentration in vivo . A second reason to propose a quantitative effect is that Ras and Rap1 activation is detected in thymocytes undergoing both positive and negative selection (Amsen et al., 2000) . Genetic deletion or inactivation of RasGRP1 dampens, but does not completely abrogate, TCR-dependent Ras activation (Priatel et al., 2002; Layer et al., 2003) . While peripheral T cell numbers and TCR-dependent proliferative responses are greatly reduced, RasGRP1 defects lead to T cell-mediated autoimmunity resembling SLE. This is attributed to abnormal thymic selection, where weakened Ras pathways fail to deliver signals sufficient for negative selection of thymocytes bearing autoreactive TCRs. RapV12, possibly via integrin-dependent mechanisms, can promote positive selection of thymocytes with low antigen affinity (Sebzda et al., 2002) . By analogy with RasGRP-deficiency, Rap1 activation could possibly strengthen thymocyte interactions with APCs to promote negative selection of autoreactive T cells. Consistent with this hypothesis, we found that the size of the MOG-autoreactive T cell pool was reduced by approximately one third in TCR transgenic animals expressing RapV12. A similar albeit smaller effect was observed by tetramer analysis in animals with a normal TCR repertoire, excluding a bias due to the specific TCR receptor of the 2D2 mice. Preliminary experiments failed to reveal gross abnormalities in thymocyte developmental subset frequencies in 2D2+RapV12+ mice (own unpublished observations). However, as the ability of Rap1 to influence thymic selection is sensitive to TCR affinity, subtle differences not identified in our studies may eventually impact upon the size of the peripheral autoreactive T cell pool (Sebzda et al., 2002) . Our observation that the 2D2 autoreactive pool is reduced not only in immunized but also in MOG-naïve animals supports the hypothesis that Rap1 signaling could affect central tolerance (Minato et al., 2007) . Together with the recent observation that pathology in EAE is mainly caused by low affinity tetramer-negative T cells (Sabatino et al., 2011) , these data warrant further detailed investigation of how Rap1 affects positive and negative selection of T cells, and their maintenance in the periphery, depending on the TCR affinity for autoantigen.
Our data indicate that sustained Rap1 signaling has complex qualitative and quantitative impacts on autoreactive T cells, raising the key question as to how these multiple effects integrate in vivo to modulate autoimmune disease. In line with our previous CIA data, we demonstrated here that RapV12 attenuates EAE, even though it should be noted that the clinical effect was probably more modest than in the CIA model (Abreu et al., 2010) . In the 2D2 model, this partial protection was only significant for survival but not for incidence or severity of EAE. This is probably due to the fact that the disease susceptibility conferred by the TCR background is too large to allow modulation of clinical disease. Accordingly, the protection of the RapV12 mice was clearer on a WT TCR background. In this regard, it is noteworthy that T cell RapV12-mediated attenuation of disease severity in EAE was not as complete as observed in CIA. This is likely due to the specific suppression of auto-antibodies in CIA and the pronounced requirement for anti-collagen antibodies in this model (Abreu et al., 2010; Bevaart et al., 2010) . EAE is less dependent on autoantibodies and we did not observe significant modulation of the anti-MOG antibodies by RapV12 (our own unpublished data). Secondly, the previously mentioned effect of RapV12 on TNFα production by T cells is thought to be more relevant for synovial inflammation in autoimmune arthritis than for CNS damage in EAE. Thirdly, RapV12 may also affect other aspects of (autoimmune) T cell biology which were not analyzed in detail in the present study. Of particular interest is the recent evidence that signaling pathways downstream of Ras GTPases can regulate the temporal expression of adhesion molecules involved in T cell trafficking Sinclair et al., 2008) . Certainly in EAE where autoreactive T cells need to cross the blood-brain barrier and home to the central nervous system, future studies will be needed to determine if therapeutic manipulation of Rap1 activity can alter recruitment and retention of autoreactive T cells at the site of inflammation.
In conclusion, the present study provides evidence demonstrating that Rap1 signaling impacts upon autoimmune T cells at different levels, and confirms the concept that sustained Rap1 activation dampens T cellmediated autoimmunity. Therefore, Rap1 signaling forms an attractive target for pharmacological modulation of pathogenic T cells in immunemediated inflammatory diseases.
Supplementary related to this article can be found online at http:// dx.doi.org/10.1016/j.jneuroim.2012.05.012.
